Published in Blood on October 01, 2002
Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure. Proc Natl Acad Sci U S A (2005) 3.93
CD177: A member of the Ly-6 gene superfamily involved with neutrophil proliferation and polycythemia vera. J Transl Med (2004) 1.00
Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and -133a. J Transl Med (2009) 1.00
Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies. Clin Epigenetics (2011) 0.87
Recent advances in the bcr-abl negative chronic myeloproliferative diseases. J Transl Med (2006) 0.80
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet (2009) 3.21
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol (2005) 2.70
TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood (2011) 2.07
Cloning and expression of murine Ig genes from single B cells. J Immunol Methods (2009) 1.73
Carbon monoxide inhalation reduces pulmonary inflammatory response during cardiopulmonary bypass in pigs. Anesthesiology (2008) 1.64
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol (2012) 1.58
CXCR4 chemokine receptors (CD184) and alpha4beta1 integrins mediate spontaneous migration of human CD34+ progenitors and acute myeloid leukaemia cells beneath marrow stromal cells (pseudoemperipolesis). Br J Haematol (2003) 1.56
Volatile anesthetics induce caspase-dependent, mitochondria-mediated apoptosis in human T lymphocytes in vitro. Anesthesiology (2005) 1.55
Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood (2003) 1.54
Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study. Haematologica (2005) 1.50
Thiopental inhibits the activation of nuclear factor kappaB. Anesthesiology (2002) 1.47
The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera. Br J Haematol (2005) 1.45
Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res (2005) 1.33
Atypical and classical memory B cells produce Plasmodium falciparum neutralizing antibodies. J Exp Med (2013) 1.31
Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF-E2. Br J Haematol (2005) 1.26
Development of self-reactive germinal center B cells and plasma cells in autoimmune Fc gammaRIIB-deficient mice. J Exp Med (2010) 1.25
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer (2006) 1.23
Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignancies. Blood (2012) 1.18
The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients. Blood (2005) 1.17
Studies on the anti-inflammatory activity of phytopharmaceuticals prepared from Arnica flowers. Planta Med (2002) 1.13
Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J Clin Oncol (2002) 1.10
Epithelial tissue chimerism after human hematopoietic cell transplantation is a real phenomenon. Am J Pathol (2004) 1.07
Of mice and men: human RNA polymerase III promoter U6 is more efficient than its murine homologue for shRNA expression from a lentiviral vector in both human and murine progenitor cells. Exp Hematol (2010) 1.06
DeltaF508-CFTR causes constitutive NF-kappaB activation through an ER-overload response in cystic fibrosis lungs. Biol Chem (2002) 1.05
A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. J Exp Med (2012) 1.05
AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2. Blood (2010) 1.05
JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling. Exp Hematol (2007) 1.05
Homeostatic expansion of autoreactive immunoglobulin-secreting cells in the Rag2 mouse model of Omenn syndrome. J Exp Med (2010) 1.03
Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h. Anticancer Drugs (2003) 1.00
MPN patients harbor recurrent truncating mutations in transcription factor NF-E2. J Exp Med (2013) 0.95
Identification of beta-subunit of bacterial RNA-polymerase--a non-species-specific bacterial protein--as target of antibodies in primary biliary cirrhosis. Dig Dis Sci (2003) 0.95
NF-E2 overexpression delays erythroid maturation and increases erythrocyte production. Br J Haematol (2009) 0.95
Pancreatic carcinosarcoma. Case report of multimodal therapy and review of the literature. JOP (2008) 0.92
The mitogen-activated protein kinase p38 regulates activator protein 1 by direct phosphorylation of c-Jun. Int J Biochem Cell Biol (2007) 0.91
Molecular genetic analyses in familial and sporadic congenital primary erythrocytosis. Haematologica (2007) 0.90
Activation of cellular death programs associated with immunosenescence-like phenotype in TPPII knockout mice. Proc Natl Acad Sci U S A (2008) 0.90
Thiopental protects human T lymphocytes from apoptosis in vitro via the expression of heat shock protein 70. J Pharmacol Exp Ther (2008) 0.89
Thionamides inhibit the transcription factor nuclear factor-kappaB by suppression of Rac1 and inhibitor of kappaB kinase alpha. J Pharmacol Exp Ther (2007) 0.89
CNS Hodgkin lymphoma. Blood (2008) 0.89
Subcellular mislocalization of the transcription factor NF-E2 in erythroid cells discriminates prefibrotic primary myelofibrosis from essential thrombocythemia. Blood (2013) 0.87
Paclitaxel pharmacokinetics and response to chemotherapy in patients with advanced cancer treated with a weekly regimen. Anticancer Res (2005) 0.87
Isoflurane pretreatment lowers portal venous resistance by increasing hepatic heme oxygenase activity in the rat liver in vivo. J Hepatol (2004) 0.87
Haematopoietic stem cell survival and transplantation efficacy is limited by the BH3-only proteins Bim and Bmf. EMBO Mol Med (2012) 0.86
Differential effects of volatile anesthetics on hepatic heme oxygenase-1 expression in the rat. Anesthesiology (2002) 0.85
Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms. Haematologica (2013) 0.84
p38β-regulated induction of the heat shock response by carbon monoxide releasing molecule CORM-2 mediates cytoprotection in lung cells in vitro. Eur J Pharmacol (2011) 0.84
Sevoflurane inhibits phorbol-myristate-acetate-induced activator protein-1 activation in human T lymphocytes in vitro: potential role of the p38-stress kinase pathway. Anesthesiology (2004) 0.84
Krüppel-like factor 15 regulates BMPER in endothelial cells. Cardiovasc Res (2009) 0.84
Inhibition of activator protein 1 by barbiturates is mediated by differential effects on mitogen-activated protein kinases and the small G proteins ras and rac-1. J Pharmacol Exp Ther (2004) 0.84
Essential versus reactive thrombocythemia in children: retrospective analyses of 12 cases. Pediatr Blood Cancer (2007) 0.84
Chromosomal abnormalities and molecular markers in myeloproliferative disorders. Semin Hematol (2005) 0.83
Barbiturates directly inhibit the calmodulin/calcineurin complex: a novel mechanism of inhibition of nuclear factor of activated T cells. Mol Pharmacol (2004) 0.83
Ponatinib: a third-generation inhibitor for the treatment of CML. Recent Results Cancer Res (2014) 0.82
Clinical and hematological presentation of children and adolescents with polycythemia vera. Ann Hematol (2009) 0.82
Familial polycythemia vera with Budd-Chiari syndrome in childhood. Br J Haematol (2003) 0.82
Sevoflurane-mediated activation of p38-mitogen-activated stresskinase is independent of apoptosis in Jurkat T-cells. Anesth Analg (2008) 0.81
Reduced intensity conditioning compared to standard conditioning preserves the in vitro growth capacity of bone marrow stroma, which remains of host origin. Stem Cells Dev (2005) 0.81
Elevated nuclear factor erythroid-2 levels promote epo-independent erythroid maturation and recapitulate the hematopoietic stem cell and common myeloid progenitor expansion observed in polycythemia vera patients. Stem Cells Transl Med (2013) 0.79
Incidence of monoclonal B-cell disease in siblings of patients with multiple myeloma. Haematologica (2006) 0.78
Estrogenic and antiestrogenic regulation of MMP-2 and MMP-13 mRNA in RUCA-I endometrial tumor cells in vitro and in vivo. Cancer Lett (2003) 0.78
Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia. Haematologica (2006) 0.78
Thiopental inhibits tumor necrosis factor alpha-induced activation of nuclear factor kappaB through suppression of kappaB kinase activity. Anesthesiology (2003) 0.78
Regulation of the adaptor molecule LAT2, an in vivo target gene of AML1/ETO (RUNX1/RUNX1T1), during myeloid differentiation. Br J Haematol (2011) 0.78
Thrombotic and bleeding complications in four subpopulations of patients with essential thrombocythemia defined by c-Mpl protein expression and PRV-1 mRNA levels. Haematologica (2005) 0.77
Molecular markers for the diagnosis of Philadelphia chromosome negative myeloproliferative disorders. Pathol Biol (Paris) (2004) 0.77
Clinical and molecular characterisation of a prospectively collected cohort of children and adolescents with polycythemia vera. Br J Haematol (2008) 0.77
Dobutamine inhibits phorbol-myristate-acetate-induced activation of nuclear factor-kappaB in human T lymphocytes in vitro. Anesth Analg (2004) 0.77
Reticulated platelet counts correlate with treatment response in patients with idiopathic thrombocytopenic purpura and help identify the complex causes of thrombocytopenia in patients after allogeneic hematopoietic stem cell transplantation. Cytometry B Clin Cytom (2007) 0.76
Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial. BMC Cancer (2013) 0.75
Repression of T-cell function by thionamides is mediated by inhibition of the activator protein-1/nuclear factor of activated T-cells pathway and is associated with a common structure. Mol Pharmacol (2007) 0.75
Fatal outcome in a patient with metastatic prostate cancer and acquired severe hypogammaglobulinemia with complete absence of mature peripheral blood B-cells. In Vivo (2003) 0.75
Comparison of methods for polycythemia rubra vera-1 mRNA quantification in whole-blood leukocytes and purified granulocytes. Clin Chem (2004) 0.75